Besides sharing the platform technology with other pharmaceutical companies for new drug development, CRM Therapeutics focuses on the development of its own proprietary therapeutics:
Apoptin is a well-known therapeutic development that systematically programs cancer cells to die. Former developments of Apoptin failed because sofar, there was no possibility to deliver it within the cancer cells. With the present delivery system, CRM Therapeutics aims to become successful with Apoptin as a new and additional treatment of cancer.
Doxotin is being developed to target cytotoxic doxorubicin into cancer cells, but also into white blood cells comprising a large part of the cancer micro environment. This will result in a substantially more effective cancer therapy, including treatment of the cancer-micro environment and largely avoiding drug resistance. In addition, it is expected that this will be established at a much smaller dose and causing less side-effects.
Cerebral Amyloid Angiopathy (CAA) is a life threatening disease that occurs frequently (1:4) in the population above 60 years. CAA is caused by β-amyloid aggregationin the cerebral blood vessels which leads to bleeds, that damage the brain. With Amytin, an siRNA-based drug, that will be targeted into the cerebral endothelial cells, CRM Therapeutics aims to prevent for CAA by breaking down and decreasing the amount of β-amyloid proteins.
Vadimezan (also known as or ASA404 and DMXAA) is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a maligne tumor to cause tumor regression. Although the development was promising, eventually the project failed due to the difference between the Sting pathways between mice and human. CRM Therapeutics combined Vadimezan with its proprietary delivery system, which solved the issues and possibly makes Vadimezan a very promising adjuvant cancer-treatment.
